Baxter launches Sharesource 2.0 telehealth platform to support greater clinical insights and personalized peritoneal dialysis care

Remote PD Management

  • Enhancements designed to give healthcare providers access to more comprehensive treatment data and improve clinic workflow

     

  • New study further supports value of remote patient management technology to personalize dialysis treatments, reduce alarms and in-person visits, while saving clinicians and patients significant time
PDF
Deerfield, Ill.

This content originates from Baxter International Inc. prior to the company establishing its chronic kidney care and acute therapies businesses into one standalone company, Vantive. This content might contain references to products/brands/persons/services that are not applicable or relevant at the present time. Please contact us in case of any questions.

Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today the launch of the Sharesource 2.0 clinical portal to give healthcare providers greater insights to their patients' home peritoneal dialysis (PD) treatments, while offering improved clinic workflow. Healthcare providers will now receive more comprehensive patient treatment summaries from the remote patient management platform, including trending ultrafiltration data, so they can make better informed and more timely treatment decisions.

 

Sharesource, the most widely adopted telehealth platform globally for home dialysis, has helped manage more than 7 million PD treatments in more than 40 countries. Supporting its broad adoption, there is growing evidence the remote patient management technology assists healthcare providers with early detection and intervention of catheter issues1, 2, 3, 4,peritonitis5, and adherence-related6, 7, 8 complications, which can lead to reduced hospitalizations9.


 

“

While the global patient population requiring dialysis is growing, the number of clinicians and their resources are not increasing," says Laura Angelini, general manager, Baxter’s Renal Care business. "For this reason, we are committed to transforming renal care through meaningful innovations like Sharesource that support better care options for both clinicians and patients.

Laura Angelini

General manager, Baxter’s Renal Care business

Sharesource 2.0 features a new clinical dashboard that provides:

  • A more comprehensive patient treatment summary to enable faster clinical insights
  • Trending total ultrafiltration data to help make informed decisions about treatment effectiveness
  • Improved workflow to triage and review patient dashboards faster

In a recent independent, observational study, "Longitudinal Experience with Remote Monitoring for Automated Peritoneal Dialysis Patients," in Nephron Clinical Practice, 2019, researchers described how the PD center at San Bortolo Hospital (Vicenza, Italy) altered its clinical practice following the implementation of remote patient management with Sharesource.

 

The study observed 43 patients using Baxter’s HomeChoice Claria with Sharesource over a one-year period, compared to a historical control (42 patients on automated peritoneal dialysis (APD) without Sharesource). They found prescription changes for patients managed with Sharesource nearly doubled, while night alarms and in-person visits were significantly reduced. Further findings indicated remote patient management supports significant time savings—approximately 105 hours per year—for the physicians and nurses collectively at the San Bortolo Hospital. This suggests remote patient management can achieve time and cost savings for providers and patients by allowing for a more personalized therapy regime and early detection and resolution of technical problems. 

 

The Sharesource 2.0 update is live on Baxter's Amia and HomeChoice Claria APD systems across Europe, Canada, Latin America and the United States, and will be live later this year across Asia where Kaguya and HomeChoice Claria are available.

About peritoneal dialysis

People living with end-stage renal disease require dialysis treatment or a kidney transplant to stay alive. PD therapy is typically managed by patients in their home, at a time of day that is convenient for them. It works by cleaning the blood of toxins and removing extra fluid through the body’s peritoneal cavity.

About Vantive

Vantive is a vital organ therapy company on a mission to extend lives and expand possibilities for patients and care teams everywhere. For 70 years, our team has driven meaningful innovations in kidney care. Today, patients across more than 100 countries around the world interact with Vantive’s people, solutions and services over 1 million times each day. As we build on our legacy, we are deepening our commitment to elevating the dialysis experience through digital solutions and advanced services, while looking beyond kidney care and investing in transforming vital organ therapies. Greater flexibility, efficiency and therapy administration for care teams, and longer, fuller lives for patients— that is what Vantive aspires to deliver. To learn more, visit www.vantive.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.

Rx Only. For safe and proper use of the devices mentioned herein, refer to the complete instructions in the Operator's Manual.

 

This release includes forward-looking statements concerning Amia, HomeChoice Claria, Kaguya and Sharesource, including anticipated availability and potential benefits associated with their use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

 

Baxter, Amia, HomeChoice Claria, Kaguya and Sharesource are registered trademarks of Baxter International Inc.

References

  1. Jiménez S & Condia J. Abstract presented at 17th ISPD congress. Vancouver (Canada). 2018. [P-337]

  2. Garcia I, et al. Abstract presented at 13th Euro-PD congress. Dublin (Ireland). 2017. [P-63]

  3. Jotterand Drepper V, et al. Abstract presented at ASN Kidney Week congress. Chicago (US). 2016. [SA-PO023]

  4. Rojas-Diaz M, et al. Abstract presented at ASN Kidney Week congress. New Orleans (US). 2017. [PUB344]

  5. Gomez R, et al. Abstract presented at 13th Euro-PD congress. Dublin (Ireland). 2017. [P-222]

  6. Jiménez S & Condia J. Abstract presented at 17th ISPD congress. Vancouver (Canada). 2018. [P-229]

  7. Firanek C, et al. Abstract presented at 54th ERA-EDTA congress. Madrid (Spain). 2017. [MP557]

  8. Jotterand Drepper V, et al. Perit Dial Int. 2018; 38:76–78; 10. Rojas-Diaz M & Ramos A. Abstract presented at ASN Kidney Week congress. New Orleans (US). 2017. [TH-PO859]

  9. Rivera A, et al. Abstract presented at ASN Kidney Week congress. San Diego (US). 2018. [FR-PO683]